Werner, Rudolf A.
Sheikhbahaei, Sara
Jones, Krystyna M.
Javadi, Mehrbod S.
Solnes, Lilja B.
Ross, Ashley E.
Allaf, Mohamad E.
Pienta, Kenneth J.
Lapa, Constantin
Buck, Andreas K.
Higuchi, Takahiro
Pomper, Martin G.
Gorin, Michael A.
Rowe, Steven P.
Funding for this research was provided by:
Horizon 2020 Framework Programme (Marie Sklodowska-Curie grant agreement)
National Institutes of Health (CA124675, CA184228, CA183031)
Prostate Cancer Foundation Young Investigator Award
Article History
Received: 4 August 2017
Accepted: 7 August 2017
First Online: 22 August 2017
Compliance with ethical standards
:
: MGP is a coinventor on a US Patent covering <sup>18</sup>F-DCFPyL, and as such is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. MAG has served as a consultant to Progenics Pharmaceuticals, the licensee of <sup>18</sup>F-DCFPyL. MAG, KJP, MGP, and SPR have received research support from Progenics Pharmaceuticals.
: The Prostate Cancer Foundation Young Investigator Award, philanthropy raised by the James Buchanan Brady Urological Institute, and National Institutes of Health Grants CA134675 and CA183031. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie Grant agreement.